By $11.22 Million Senzar Asset Management Llc Trimmed its Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)

May 17, 2018 - By Megan Stone

During 2017 Q4 the big money sentiment decreased to 1.2. That’s change of 0.53, from 2017Q3’s 1.73. 23 investors sold all, 48 reduced holdings as AERI ratio dived. 64 rose positions while 21 funds took positions. Funds hold 34.86 million shares thus 1.29% more from 2017Q3’s 34.42 million shares. Ameriprise has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Sectoral Asset Management holds 2.75% or 368,797 shs in its capital. Teachers Retirement Sys Of The State Of Kentucky accumulated 0.04% or 62,720 shs. Parallax Volatility Advisers Lp stated it has 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Driehaus Capital Ltd Com reported 75,995 shs stake. Axiom Invsts Limited Company De stated it has 44,689 shs or 0.07% of all its holdings. Mirae Asset Invs Ltd has 0.03% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 39,357 shs. Next Century Growth Invsts Llc has 0.69% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Brown Brothers Harriman holds 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 113 shs. Guggenheim Ltd Llc reported 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Parkside Bankshares & Tru stated it has 229 shs or 0.01% of all its holdings. Susquehanna International Grp Inc Llp, a Pennsylvania-based fund reported 178,957 shs. Vanguard Gru Incorporated holds 0.01% or 3.06 million shs in its capital. Citadel Advsr Limited Liability Corp owns 34,903 shs or 0% of their US capital. 14,512 were accumulated by Legal And General Group Public Limited Co.

The stake In Aerie Pharmaceuticals Inc (NASDAQ:AERI) owned by Senzar Asset Management Llc was reduced. According to 2018Q1 Securities and Exchange form the decrease is 74.62%. The company’s stock Sank 12.77% while Senzar Asset Management Llc sold 207,732 shares. At the end of 2018Q1, the 70,668 shares of the health care company held by the hedge fund were valued at $3.83M, down from 278,400 at the end of the previous reported quarter. $2.02B is the MC of Aerie Pharmaceuticals Inc. The stock increased 1.59% or $0.8 during the last trading session, hitting $51.2.Aerie Pharmaceuticals, Inc. has volume of 224,990 shares. Since May 17, 2017 AERI has risen 16.25% and is uptrending. AERI outperformed by 4.70% the S&P 500.

Senzar Asset Management Llc has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NASDAQ:AERI)’s analyst reports since December 18, 2017 according to StockzIntelligence Inc. On Wednesday, February 28 the rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, May 8 the rating was maintained by Cantor Fitzgerald with “Buy”. On Wednesday, May 9 H.C. Wainwright maintained the shares of AERI in report with “Buy” rating. On Friday, February 16 the company was reinitiated by H.C. Wainwright. On Wednesday, May 9 the firm has “Buy” rating by Mizuho given. The stock rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, January 2. On Thursday, March 1 the stock has “Buy” rating by H.C. Wainwright. On Monday, December 18 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Cantor Fitzgerald. The stock rating was maintained by Mizuho with “Buy” on Thursday, March 29. In Wednesday, January 24 report Canaccord Genuity maintained it with “Buy” rating and $86.0 target.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is valued at $2.02 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: